(Q36338026)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341237%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341237%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341237%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Jean-Pierre Issa

series ordinal

1

1 reference

13 August 2017

1 December 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341237%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341237%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

2 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341237%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

S24-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341237%20AND%20SRC:MED&resulttype=core&format=json

5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

Myelodysplastic syndromes. Diagnosis and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Myelodysplastic syndrome overview

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Eukaryotic DNA methylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

DNA modification, differentiation, and transformation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

5-azacytidine in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Decitabine in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Targeted therapies in myelodysplastic syndromes: ASH 2003 review

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0355

1 reference

7 January 2021

Cellular differentiation, cytidine analogs and DNA methylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0355

1 reference

7 January 2021

Epigenetic targets for immune intervention in human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0355

7 January 2021

Identifiers

DOI

10.1038/NCPONC0355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16341237%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference